CA-CONSENSUS-CLOUD
14.10.2021 13:02:12 CEST | Business Wire | Press release
Consensus Cloud Solutions, Inc. (NASDAQ: CCSI) (“Consensus”) started as a secure digital document transmission solution more than 25 years ago and has grown to be a leading global digital cloud fax technology. On October 8, 2021, Consensus Cloud Solutions started publicly trading as an independent company focused on serving compliance and data-driven organizations in the healthcare, financial, manufacturing and legal industries.
The Consensus solution suite will do more than transport documents securely. In the Consensus workflow, the document is enhanced through application of advanced Natural Language Processing, Machine Learning and Artificial Intelligence technologies to transform unstructured documents to structured intelligent data – enabling the easy extraction of meaningful insights. This data exchange technology supports HL7/FHIR and direct message protocols and can be used to accelerate critical decision-making processes.
The direction of the new Consensus solution suite creates an opportunity to focus on the growing need for secure, intuitive ways to access, transform, enhance and exchange actionable data using innovative market-leading interoperability capabilities.
“The exciting aspect of Consensus existing as its own public company is that now we get to dictate the pace of innovation in bringing new products and services to market,” said Scott Turicchi, Chief Executive Officer of Consensus Cloud Solutions, Inc. “Our first obligation is to the healthcare market, assisting providers, payers and caregivers to improve communications. In addition, because we deal with regulated organizations, much of what we offer can apply to document-reliant industries such as legal, financial and manufacturing.”
The Consensus healthcare interoperability suite of secure solutions offers the following features:
- A unified digital environment that optimizes workflows
- Real-time health event notifications
- On-demand patient query
- Direct secure messaging
- Universal APIs
- Natural Language Processing/Artificial Intelligence
- Electronic signature
- eFax HITRUST CSF® Certified digital cloud faxing
About Consensus Cloud Solutions, Inc.
Consensus Cloud Solutions, Inc. (NASDAQ: CCSI) has been a global leader of digital cloud fax technology for over 25 years. The company leverages its technology heritage to provide secure solutions that transform simple digital documents into advanced healthcare standard HL7/FHIR for secure data exchange. Consensus offers eFax, a global leader in online faxing, Consensus Unite and Consensus Harmony interoperability solutions, Consensus Signal for secure automatic real-time healthcare communications, Consensus Clarity, an Optical Character recognition (OCR) and Natural Language Processing (NLP) solution, and jSign for electronic digital signatures. For more information about Consensus, visit consensus.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005264/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ThetaRay Named World’s Best Software Provider for AML and Sanctions Screening in the 2026 Euromoney Transaction Banking Awards5.11.2026 19:30:00 CET | Press release
Recognition caps standout year alongside ThetaRay’s Top 10 (#8) ranking in the 2026 Chartis Financial Crime and Compliance50 (FCC50) and category win for Explainable AI. ThetaRay, a global leader in AI-native financial crime compliance infrastructure, has been named The World’s Best Software Provider for AML and Sanctions Screening at the 2026 Euromoney Transaction Banking Awards. Evaluated by Euromoney’s editorial and research team, ThetaRay was recognized for technology excellence, verifiable performance, and advancing the modern transaction banking value chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105714764/en/ The recognition reinforces ThetaRay’s standing as foundational compliance infrastructure for global institutions, closely following Chartis Research ranking ThetaRay #8 globally in the Financial Crime and Compliance50 (FCC50) 2026 report and naming the company a Category Winner for Explainable AI. “Our
Arthur D. Little: H1 2026 Private Capital Fundraising Strengthens While Market Sentiment Highlights Investor Shift to Europe over US and Asia5.11.2026 18:58:00 CET | Press release
H1 fundraising up 6% year-on-year as 43% of LPs see geopolitical volatility favouring European funds AI usage dominates industry attention, defence leads target investment themes Invest Europe, the association representing Europe’s private equity, venture capital and infrastructure sectors, as well as their investors, today released ‘Investing in Europe: Private Equity Activity H1 2026’ and ‘The Insight: State of the European Private Equity Industry 2026’, an annual market sentiment report published jointly with global management consultancy Arthur D. Little (ADL). Together, these show increased fundraising for European private equity and venture capital versus the same period last year, stronger investor allocation expectations for Europe, and declining appetite for the US and Asia. The sentiment report also demonstrates how AI is reshaping the industry and portfolio companies, while defence-related themes are topping GPs’ target investments. GPs (General Partners/fund managers of PE
Angelalign Appoints Marco Gadola as Senior Advisor5.11.2026 18:35:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel”) http://www.angelaligner.com, a global clear aligner leader, today announced that Marco Gadola has joined Angel as Senior Advisor. In this role, Marco will advise the Board and senior management on culture, strategy and governance. Marco, who has held many leadership positions, is well-known as a former CEO of Straumann Group, a leading global medical device company focused on dentistry. Marco said he is excited to join Angel. “I’ve followed Angel for 10 years and have seen how it has evolved,” he said, “It’s grown from a regional leader in innovative clinical solutions and high-quality products, to a worldwide organization trusted by orthodontic specialists, with an impressive innovation pipeline.” Fox Hu, CEO of Angel, said: “Angel has strong core capabilities, but we must continue to improve to serve orthodontists even better. We welcome Marco as an advocate for our customers and employees around the world and to help us build an outstan
Boomi Named a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms5.11.2026 17:25:00 CET | Press release
Boomi governs agents, with flexibility across cloud, hybrid, and fully on-premises deployments behind the firewall. Boomi, the data activation company for AI, today announced it has been recognized as a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms. Boomi delivers agent management capabilities through the Agent Control Plane. Boomi believes this placement reflects its approach to solving one of the biggest hurdles in turning AI into ROI, by providing critical AI infrastructure that connects, governs, and controls AI costs across agents and skills from native and third-party providers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105515847/en/ Boomi Named a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms Key Takeaways Boomi has been recognized as a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms. A complimentary copy of t
Biocodex Invests €15 Million in a New Industrial Platform for Live Biotherapeutic Products5.11.2026 16:04:00 CET | Press release
Biocodex, an independent French pharmaceutical company, announces a €15 million investment to develop an industrial platform in Beauvais, France, dedicated to Live Biotherapeutic Products (LBPs) derived from the microbiome. Building on more than 70 years of expertise in living microorganisms, microbiota, fermentation and pharmaceutical manufacturing, Biocodex aims to support its partners and, ultimately, its own programs, from research through to clinical and commercial production. The project aims to strengthen healthcare and industrial sovereignty in the field of next-generation microbiome-based therapies. Scientific advances in microbiome science are opening up new therapeutic perspectives, notably in oncology, inflammatory bowel diseases, certain rare diseases and women’s health. Moving from research to pharmaceutical production requires facilities adapted to living microorganisms and pharmaceutical requirements. Open to biotechnology companies worldwide, it will support LBP progra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom